Fig. 3. Systemic treatment of Mito-Q ameliorated liver injury, bradykinesia, and mitochondrial dysfunction induced by TAA.
a Schematic flow chart to show the strategy. b H&E staining in TAA mice (TAA group) and Mito-Q-treated TAA mice (Mito-Q group) (Bar = 100 μm on the top and Bar = 30 μm on the bottom). c, d The serum levels of ALT and AST (n = 6 per group). e, f Ammonia levels in blood and brain (n = 6 per group). g, h Elisa results of antioxidative biomarkers of SOD and GPx in the blood (n = 7, 6 per group). i Schematic traces and analysis of the run time and average speed of the CatWalk test (n = 7). j Behavioral results of rotarod test (n = 7 per group). k Schematic traces and analysis of the total distance and average speed of open field test (n = 8, 9 per group). l ROS staining in the SNr of GAD2-Mito mice and quantitative analysis of ROS staining within SNr (n = 4 per group, Bar = 100 μm or 30 μm). m Western blot results and analysis of UCP2, SOD1, and GPX1 expression in SNr. n Western blot results and analysis of LC3B and PINK1 expression in SNr. o Western blot results and analysis of DRP1, p-DRP1(Ser616), MFN2, MFF, and FIS1 expression in SNr. Data are presented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs TAA. n = 3 per group in western blotting. Two-tailed, unpaired, Student’s t-test for all data except one-way ANOVA with LSD’s multiple comparison tests for l. Source data are provided as a Source Data file.